(Wall) Street Value: Investors Betting Big on Bud | Marijuana

(Wall) Street Value: Investors Betting Big on Bud

0

By, Marley Jay

NEW YORK (AP) — Reefer madness has gripped Wall Street.

Investors are craving marijuana stocks as Canada prepares to legalize cannabis in October 2018, leading to giant gains for Canada-based companies listed on U.S. exchanges. Some experts are concerned that the ending will be a buzzkill.

Billions of dollars have poured into the stocks in much of 2018, and investors smell green — money, not leaves — in the air as they consider the opportunities these companies might have as the cannabis market in Canada grows, along with the possibility that the U.S. and other countries could follow suit.

The value of one company, British Columbia-based Tilray, has jumped tenfold since its initial public offering in July 2018. The company had $20 million in sales in 2017, but it’s now worth considerably more than Macy’s or Hasbro. With those huge gains have come extreme swings.

Wednesday, Sept. 19, 2018, was a trip for Tilray stock: After closing at $154 the previous day, it opened at $233 a share, soared to $300, and then plunged to $151 before rallying to close at $214. Trading was halted several times because of that volatility.

For some people on Wall Street, it’s bringing back unpleasant memories.

“We just went through this eight months ago with cryptocurrencies,” said investor Ken Mahoney, CEO of New York-based Mahoney Asset Management. He said the investors buying these stocks at their current prices are already betting on enormous successes, but even if legal marijuana takes off, some of the companies will fail.

It’s easy to see why investors are so optimistic. On Tuesday, Sept. 18, 2018, Coca-Cola acknowledged it could one day offer cannabis-infused drinks. That came after reports the soft drink giant was in talks with Aurora Cannabis about drinks containing cannabidiol (CBD). Aurora stock, which is listed in Canada, surged. That would be a sort of return to Coca-Cola’s roots, as the drink contained some cocaine when it was invented in 1886 and served in an Atlanta pharmacy.

Molson Coors said In August 2018 that it will team up with Hydropothecary Corp. to sell marijuana-infused drinks, and Canopy Growth announced a $4 billion investment from Constellation Brands, the company that makes Corona beer.

The stocks jumped Tuesday, Sept. 18, 2018, when the Center for Medicinal Cannabis Research at the University of California, San Diego (UCSD) said the government will allow it to import capsules containing cannabis compounds from Tilray so the center can study their effectiveness in treating tremors.

“The total global (cannabis) category could reach upwards of $200 billion, as suggested by Constellation Brands,” said Christopher Growe, analyst for investment banking and brokerage firm Stifel.

Canopy Growth has more than doubled in value this year, and another rival trading in the U.S., Cronos Group has jumped 78 percent. KushCo Holdings has surged 36 percent and GW Pharmaceuticals, which in June 2018 received government approval for a cannabis-derived drug used to treat seizures, is up 29 percent.

The Canopy Growth Corp. logo appears May 31, 2018, on a trading floor screen at the New York Stock Exchange. The Canadian marijuana business, based in Smiths Falls, Ontario, was buoyed by a $4 billion investment from American-based alcoholic beverage giant Constellation Brands, based in Victor, New York. (Associated Press File Photo/Richard Drew)

Growe said the value of the 22 largest marijuana companies trading in Canada has more than doubled since Aug. 15, 2018, when the Canopy-Constellation deal was announced.

Recreational marijuana will become legal across Canada on Oct. 17, 2018, and consumable forms of the drug will be legal in 2019. Marijuana remains illegal in the U.S. at the federal level, but it’s legal for recreational use in nine states and Washington, D.C., and for medical use in 31 states, according to the National Conference of State Legislatures.

Growe noted that governments considering marijuana legalization or similar policies are likely to move very slowly. And Mahoney said if there is a bubble, larger investors will protect themselves and won’t overinvest in single companies, but smaller investors who see a chance to get rich quickly could suffer painful losses.

“The small investors always end up with the short end of the stick,” he said. “They don’t have the insight, they don’t have the experience.”

An investor who bought Tilray stock Wednesday, Sept. 19, 2018, might have agreed, as the shares fell 18 percent to finish at $176.

Brendan Kennedy is CEO and founder of Tilray Inc., which had a wild week on Wall Street in mid-September 2018. The British Columbia company listed on the U.S. Nasdaq exchange saw its stock gyrate from a high of $300 to a low of $151 in a single trading day. Trades had to be halted because of the volatility. (Associated Press File Photo/Bebeto Matthews)

Tilray Inc CEO and founder Brendan Kennedy, third from right in front, basks in a confetti shower July 19, 2018, when the British Columbia-based cannabis company had its initial public offering (IPO) on the Nasdaq exchange in New York. Upon news that Tilray was authorized to supply cannabis capsules to the University of California San Diego (UCSD) for a research study, the firm’s stock closed at $154 on Tuesday, Sept. 18, 2018, and opened with a $233 per share value the next morning. (Associated Press File Photo/Bebeto Matthews)

The Canopy Growth Corp. logo appears May 31, 2018, on a trading floor screen at the New York Stock Exchange. The Canadian marijuana business, based in Smiths Falls, Ontario, was buoyed by a $4 billion investment from American-based alcoholic beverage giant Constellation Brands, based in Victor, New York. (Associated Press File Photo/Richard Drew)

About Author

Leave A Reply